SCHEMBL25072766

SCHEMBL25072766

O=C(O)c1ccc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)c(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.42
▸ MAP4K4 O95819 2/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ VNN1 O95497 2/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MAPK3 P27361 1/20 0.36
▸ SLC16A3 O15427 1/20 0.36
▸ THRB P10828 1/20 0.35
▸ KDM1A O60341 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ HDAC6 Q9UBN7 2/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ STING1 Q86WV6 1/20 0.35
▸ PTGFR P43088 1/20 0.35
▸ METAP2 P50579 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25073309 0.88 THRB (0.43) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3
SCHEMBL25072760 0.87 KDM4E (0.47) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3
SCHEMBL25073359 0.86 L3MBTL1 (0.43) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3
SCHEMBL25072763 0.85 PYGL (0.42) PTPN11MAP4K4CSNK2A2CSNK2A1PTGFR
SCHEMBL25734411 0.84 PTPN11 (0.40) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3
SCHEMBL25072895 0.84 CMA1 (0.48) PTPN11MAP4K4CSNK2A2CSNK2A1NPSR1
SCHEMBL25073104 0.83 KDM4E (0.46) CSNK2A2CSNK2A1
SCHEMBL25073194 0.83 XDH (0.41) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3
SCHEMBL25072772 0.82 PTPN11 (0.39) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3
SCHEMBL25072753 0.82 PTPN11 (0.38) PTPN11MAP4K4CSNK2A2CSNK2A1SLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 PTPN11 3612/4885MAP4K4 3008/4885CSNK2A2 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback